---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-001757"
form_type: "8-K"
ticker: "PTN"
cik: "0000911216"
company_name: "PALATIN TECHNOLOGIES INC"
filed_at: "2023-02-15T23:59:59+00:00"
generated_at: "2026-06-19T12:45:59.592634+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Palatin reports Q2 FY2023 net loss $1.4M, Vyleesi net revenue up 18% QoQ

## Summary
- Net loss of $1.4M ($0.13/share) improved from $8.7M loss ($0.91) YoY; includes $4.7M tax benefit.
- Vyleesi net product revenue $1.0M, up 18% vs prior quarter; prescriptions dispensed up 12%.
- PL9643 Phase 3 dry eye trial enrollment on track; topline data expected mid-2023.
- PL8177 Phase 2 UC trial commenced; interim analysis H1 2023, topline H2 2023.
- Cash $21.2M plus $6.5M receivables; sufficient through calendar 2023.

## SEC filing metadata
- accession: 0001654954-23-001757
- form_type: 8-K
- ticker: PTN
- cik: 0000911216
- company_name: PALATIN TECHNOLOGIES INC
- filed_at: 2023-02-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/911216/000165495423001757/0001654954-23-001757-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/911216/000165495423001757/ptn_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-001757
- JSON: https://secwatch.observer/filing/0001654954-23-001757.json
- Plain text: https://secwatch.observer/filing/0001654954-23-001757.txt

## Key facts
- Earnings Releases
  PALATIN TECHNOLOGIES INC reported fiscal second quarter ended December 31, 2022 results: revenue $1 million.
  - Period: fiscal second quarter ended December 31, 2022
  - Revenue: $1 million
  - Result: reported results
  source text: value metrics, notably net product sales increased 18% and prescriptions dispensed increased 12% over the prior quarter. We are excited that net product revenue of approximately $1 million for the quarter ended December 31, 2022, exceeded Vyleesi operating expenses.” Business Highlights and Recent Updates · Anti-Inflammatory / Autoimmune Programs o PL9643
  evidence_url: https://www.sec.gov/Archives/edgar/data/911216/000165495423001757/0001654954-23-001757-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.